Risk factors for chronic kidney disease after chemotherapy for testicular cancer - Abstract

OBJECTIVE: To elucidate the patterns of and risk factors for deterioration of renal function after chemotherapy in metastatic testicular cancer survivors using the estimated glomerular filtration rate.

METHODS: A total of 96 patients who were treated with cisplatin-based chemotherapy for metastatic testicular cancer between January 1981 and December 2010 were enrolled in this study. The estimated glomerular filtration rate was based on the serum creatinine concentration using the formula of the Japanese Society of Nephrology. Risk factors for chronic kidney disease were examined by multivariate logistic-regression analysis.

RESULTS: The median follow-up period was 70 months (range 15-342). The median pretreatment estimated glomerular filtration rate was 98 mL/min/1.73 m2 (range 44-216), and it gradually decreased for 1 year after the end of chemotherapy, although there was no significant change in estimated glomerular filtration rate beyond 1 year. One year after chemotherapy, 22 of 96 patients (23%) showed chronic kidney disease (less than 60 mL/min/1.73 m2 estimated glomerular filtration rate). The multivariate analysis showed that the patients with mild renal damage (estimated glomerular filtration rate 60-89 mL/min/1.73 m2 ) and elevated blood pressure (higher than 130/80 mmHg) before treatment had a significant risk with odds ratios of 2.63 (95% confidence interval 1.09-6.73) and 4.22 (95% confidence interval 1.45-12.6), respectively.

CONCLUSIONS: Close monitoring of renal function is important for at least 1 year after chemotherapy for testicular cancer, especially in patients having elevated blood pressure and/or mild renal damage before chemotherapy.

Written by:
Inai H, Kawai K, Ikeda A, Ando S, Kimura T, Oikawa T, Onozawa M, Miyazaki J, Uchida K, Nishiyama H.   Are you the author?
Department of Urology, International University of Health and Welfare Hospital, Nasushiobara, Tochigi, Japan.

Reference: Int J Urol. 2012 Nov 27. Epub ahead of print.
doi: 10.1111/iju.12017

PubMed Abstract
PMID: 23186076

UroToday.com Testicular Cancer Section






email news signup